January 12, 2026 a 09:00 am
DHR: Analysts Ratings - Danaher Corporation
The analyst ratings for Danaher Corporation (DHR) indicate a stable sentiment with a strong inclination towards positive recommendations. The company operates in diverse sectors, providing resilience against market fluctuations. Recent data exhibits consistency in strong buy and buy recommendations, reflective of the company's robust market position in life sciences, diagnostics, and environmental solutions.
Historical Stock Grades
As of January 2026, the analyst ratings for Danaher Corporation remain optimistic, demonstrating confidence in the company's future prospects. The balance between strong buy and buy ratings highlights a consensus on the stock's potential for growth and sustainability in its markets.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 18 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The past months have shown steady sentiment in Danaher Corporation's stock ratings, with a consistent number of strong buy and buy ratings. Notable trends include:
- A slight decline in strong buy ratings from previous months but maintaining a strong buy consensus.
- Stable buy recommendations over recent months, underscoring confidence in ongoing growth.
- Hold recommendations have remained low, indicating fewer concerns about potential risks.
Percentage Trends
Analyzing the percentage distribution of analyst ratings reveals minor shifts in sentiment. Over recent months, the predominant sentiment remains positive, while the hold ratings reflect a watchful but optimistic outlook.
- Strong Buy: 16% of total ratings, showcasing a slight decrease from earlier peaks.
- Buy: 72% of total ratings, indicating a robust positive sentiment remains unchanged.
- Hold: 12% of total ratings, maintaining a consistent cautious outlook.
Overall, analyst ratings suggest sustained confidence in Danaher Corporation's performance.
Latest Analyst Recommendations
Recent analyst recommendations reflect a stable outlook, with most maintaining their ratings. Here are the latest updates:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-07 | Buy | Buy | TD Cowen |
| 2026-01-05 | Buy | Buy | Guggenheim |
| 2025-12-15 | Equal Weight | Equal Weight | Wells Fargo |
| 2025-10-23 | Equal Weight | Equal Weight | Wells Fargo |
| 2025-10-22 | Overweight | Overweight | Barclays |
Analyst Recommendations with Change of Opinion
Historically, the changes in analyst recommendations for Danaher Corporation illustrate a dynamic assessment of the company's performance, with some downgrades reflecting shifts in market outlooks.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-08 | Neutral | Buy | Rothschild & Co |
| 2025-07-11 | Sector Outperform | Sector Perform | Scotiabank |
| 2025-04-10 | Overweight | Equal Weight | Barclays |
| 2025-03-14 | Buy | Hold | Stifel |
| 2025-02-03 | Market Perform | Outperform | Raymond James |
Interpretation
The consistent buy ratings and stable sentiment suggest that analysts have a positive outlook on Danaher Corporation despite occasional downgrades. The balance between stability and minor downgrades could indicate growing caution amid prevailing economic uncertainties. However, the absence of sell ratings highlights continued trust in the company's strategic growth initiatives and market position stability.
Conclusion
In summary, Danaher Corporation maintains a strong analyst sentiment, particularly in its life sciences and diagnostics segments, reflecting confidence in its wide-ranging industry impact. While some ratings have shifted, the predominant buy sentiment underscores the company's resilience and potential for future growth. Investors should consider the company's strong market position but remain attentive to shifts in ratings that may signal macroeconomic shifts or industry-specific challenges.